MX2021003152A - Piridazinonas y sus metodos de uso. - Google Patents

Piridazinonas y sus metodos de uso.

Info

Publication number
MX2021003152A
MX2021003152A MX2021003152A MX2021003152A MX2021003152A MX 2021003152 A MX2021003152 A MX 2021003152A MX 2021003152 A MX2021003152 A MX 2021003152A MX 2021003152 A MX2021003152 A MX 2021003152A MX 2021003152 A MX2021003152 A MX 2021003152A
Authority
MX
Mexico
Prior art keywords
methods
formula
pyridazinones
disclosed
compounds
Prior art date
Application number
MX2021003152A
Other languages
English (en)
Inventor
Mark W Ledeboer
Matthew H Daniels
Maolin Yu
Jean-Christophe P Harmange
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of MX2021003152A publication Critical patent/MX2021003152A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de acuerdo con la Fórmula (I) y composiciones farmacéuticas relacionadas. También se divulgan métodos terapéuticos, por ejemplo, para tratar enfermedades renales, usando los compuestos de Fórmula (I). (ver Fórmula).
MX2021003152A 2018-09-18 2019-09-18 Piridazinonas y sus metodos de uso. MX2021003152A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732728P 2018-09-18 2018-09-18
US201862780553P 2018-12-17 2018-12-17
PCT/US2019/051680 WO2020061162A1 (en) 2018-09-18 2019-09-18 Pyridazinones and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021003152A true MX2021003152A (es) 2021-06-23

Family

ID=69887813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003152A MX2021003152A (es) 2018-09-18 2019-09-18 Piridazinonas y sus metodos de uso.

Country Status (22)

Country Link
US (3) US10654850B2 (es)
EP (1) EP3852533B1 (es)
JP (1) JP7474243B2 (es)
KR (1) KR20210069652A (es)
CN (1) CN112911935A (es)
AU (1) AU2019344928A1 (es)
BR (1) BR112021004926A2 (es)
CA (1) CA3113236A1 (es)
CL (1) CL2021000648A1 (es)
CO (1) CO2021004789A2 (es)
DK (1) DK3852533T3 (es)
EC (1) ECSP21026485A (es)
FI (1) FI3852533T3 (es)
IL (1) IL281438B2 (es)
MA (1) MA53670A (es)
MX (1) MX2021003152A (es)
PE (1) PE20211774A1 (es)
PH (1) PH12021550443A1 (es)
SG (1) SG11202102053VA (es)
TW (1) TWI828758B (es)
UY (1) UY38377A (es)
WO (1) WO2020061162A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852533B1 (en) 2018-09-18 2024-02-28 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
WO2022006278A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Reducing fibrosis and treating related diseases, disorders, and conditions
IL299623A (en) * 2020-07-03 2023-03-01 Wuhan Ll Science And Tech Development Co Ltd Heterocyclic compound and its use
TWI824403B (zh) * 2021-02-07 2023-12-01 大陸商武漢朗來科技發展有限公司 一種雜環化合物、其中間體、其製備方法及其應用
WO2023036312A1 (zh) * 2021-09-10 2023-03-16 南京明德新药研发有限公司 卤素取代的哒嗪酮类化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
AU2005206562A1 (en) * 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005072308A2 (en) 2004-01-29 2005-08-11 Merck & Co., Inc. Cgrp receptor antagonists
DE102004044231A1 (de) 2004-09-14 2006-03-16 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
KR20070062997A (ko) 2004-10-13 2007-06-18 머크 앤드 캄파니 인코포레이티드 Ｃｇｒｐ 수용체 길항제
EP2492263A1 (en) 2006-07-25 2012-08-29 Cephalon, Inc. Pyridizinone Derivatives
US20100158992A1 (en) 2007-03-15 2010-06-24 Schering Corporation Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
AU2008319735A1 (en) * 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as P2X7 receptor inhibitors
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
EP2611798B1 (en) * 2010-09-01 2015-04-08 Gilead Connecticut, Inc. Pyridazinones, method of making, and method of use thereof
CN104718201A (zh) * 2012-06-12 2015-06-17 艾伯维公司 吡啶酮和哒嗪酮衍生物
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
EP3852533B1 (en) 2018-09-18 2024-02-28 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
WO2020191056A1 (en) * 2019-03-20 2020-09-24 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
WO2020206623A1 (en) * 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms

Also Published As

Publication number Publication date
JP7474243B2 (ja) 2024-04-24
BR112021004926A2 (pt) 2021-06-01
TW202035402A (zh) 2020-10-01
PE20211774A1 (es) 2021-09-08
CL2021000648A1 (es) 2021-08-06
CA3113236A1 (en) 2020-03-26
US20200283437A1 (en) 2020-09-10
CN112911935A (zh) 2021-06-04
TWI828758B (zh) 2024-01-11
AU2019344928A1 (en) 2021-04-29
US11046690B2 (en) 2021-06-29
MA53670A (fr) 2021-07-28
IL281438B1 (en) 2023-08-01
EP3852533A4 (en) 2022-06-15
IL281438A (en) 2021-04-29
IL281438B2 (en) 2023-12-01
JP2022500359A (ja) 2022-01-04
EP3852533A1 (en) 2021-07-28
SG11202102053VA (en) 2021-04-29
UY38377A (es) 2020-04-30
DK3852533T3 (da) 2024-05-27
FI3852533T3 (fi) 2024-05-24
WO2020061162A1 (en) 2020-03-26
US20200102301A1 (en) 2020-04-02
ECSP21026485A (es) 2021-07-30
EP3852533B1 (en) 2024-02-28
US20220024917A1 (en) 2022-01-27
CO2021004789A2 (es) 2021-07-30
PH12021550443A1 (en) 2021-12-06
US10654850B2 (en) 2020-05-19
KR20210069652A (ko) 2021-06-11

Similar Documents

Publication Publication Date Title
WO2019055966A3 (en) PYRIDAZINONES AND METHODS OF USE
PH12021550443A1 (en) Pyridazinones and methods of use thereof
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12020551425A1 (en) Rimegepant for cgrp related disorders
CR20220207A (es) Compuestos terapéuticos y métodos de uso
PH12019501896A1 (en) Therapeutic dendrimers
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
MX2021011316A (es) Piridazinonas y metodos de uso de estas.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
WO2019028309A1 (en) AZAINDOLES AND THEIR METHODS OF USE
MX2021011081A (es) Derivados de nicorandil.
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
EA202190787A1 (ru) Пиридазиноны и способы их применения
EA202092344A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA202090969A1 (ru) Третичные спирты в качестве ингибиторов pi3k-
EA201990074A1 (ru) Гетероциклические соединения как иммуномодуляторы